JAMP CALCIUM POLYSTYRENE SULFONATE DIN 02502631
Health Canada record
| Active ingredient(s) | CALCIUM POLYSTYRENE SULFONATE 999 MG |
|---|---|
| Dosage form | Powder For Suspension |
| Route | Rectal; Oral |
| Schedule | ETHICAL |
| Class | Human |
| ATC | V03AE01 POLYSTYRENE SULPHONATE |
| Original market date | 02-May-2022 |
| Current status date | 31-Jul-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Jamp Pharma Corporation — licence 100590, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CALCIUM POLYSTYRENE SULFONATE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02017741 | RESONIUM CALCIUM | SANOFI-AVENTIS CANADA INC | Powder For Solution | CALCIUM POLYSTYRENE SULFONATE 999 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 23955 | 2020-07-23 | Abbreviated New Drug Submission (ANDS) |
International API supply for CALCIUM POLYSTYRENE SULFONATE
1 active FDA Drug Master Files.
Request a quote for JAMP CALCIUM POLYSTYRENE SULFONATE